Covaxin’s US approval delayed over data, Bharat Biotech’s partner to file for full approval | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Multimedia
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Monday
December 11, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Multimedia
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
MONDAY, DECEMBER 11, 2023
Covaxin’s US approval delayed over data, Bharat Biotech’s partner to file for full approval

Coronavirus chronicle

Hindustan Times
11 June, 2021, 01:10 pm
Last modified: 11 June, 2021, 01:13 pm

Related News

  • India gives nod to Bharat Biotech for intranasal Covid booster doses
  • WHO issues emergency use listing for COVAXIN Covid-19 jab
  • India recommends homemade Covid-19 vaccine for kids aged 2 and above
  • India to miss end-July vaccination target as Bharat Biotech lags
  • India's Bharat Biotech says regulatory steps taken for Brazil vaccine contract

Covaxin’s US approval delayed over data, Bharat Biotech’s partner to file for full approval

Ocugen, which has partnered with Bharat Biotech to produce Covaxin for US market, said it will now seek full approval for the shot

Hindustan Times
11 June, 2021, 01:10 pm
Last modified: 11 June, 2021, 01:13 pm
Photo: UNB
Photo: UNB

Bharat Biotech's partner for Covaxin in the US has said it will no longer seek an emergency use authorisation for its Covid-19 vaccine candidate and will file for a full approval of the shot after the Food and Drug Administration (FDA) asked for additional information and data. Ocugen, which has partnered with Bharat Biotech to produce Covaxin for the US market, said the decision was based on a recommendation from the country's top public health regulator.

"The FDA provided feedback to Ocugen regarding the Master File submitted previously and recommended that we pursue a BLA submission instead of an EUA application for the vaccine candidate and requested additional information and data," Ocugen, which has partnered with Bharat Biotech to produce Covaxin for the US market, said in a statement to the New York Stock Exchange (NYSE).

As a result of this, Ocugen said, it would no longer pursue a EUA application and would instead aim to file for full approval of the shot and go for a Biological License Application (BLA)—the full approval for a vaccine shot. The firm added that it expects data from an additional clinical trial to be required for a full-use application.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"While this will extend our timelines, we're committed to bringing Covaxin to the US," Ocugen chief executive officer (CEO) Dr Shankar Musunuri said. In addition to the US, Ocugen has secured exclusive rights to market the vaccine in Canada as well and is in discussion with Health Canada for regulatory approval.

Covaxin is India's only homemade vaccine against the coronavirus disease and one among three to have been approved for use; Covishield and Sputnik V are the other two shots. Of these, Covaxin and Covishield have been used since India began its vaccination drive on January 16.

The shot was found to be 78% effective against the symptomatic disease, and 100% protection from serious illness, according to the interim analysis. Bharat Biotech was to announce the results of phase three clinical trials in June but said on June 10 it would do so only a month later, in July.

Bharat Biotech Covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • File photo of Envoy Textile factory. Photo: Salauddin Ahmed Paulash/TBS
    Bangladeshi textile millers seek loan concession, increased LC limit
  • Renata puts footprint into Aussie pharma market
    Renata puts footprint into Aussie pharma market
  • Photo: UNB
    Dhaka's air 'hazardous'; worst in the world for 2nd consecutive day

MOST VIEWED

  • Photo: Times of India
    Abir Hassan, first Bangladeshi to graduate from Indian Military Academy
  • 10m barrel oil, 300b cubic feet gas found in Sylhet
    10m barrel oil, 300b cubic feet gas found in Sylhet
  •  ZARA ATELIER. Collection 04; The Jacket. Photo: Collected
    When art imitates cruelty: Dissecting Zara’s latest shoot
  • Photo: euronews
    Apps that use AI to undress women in photos soaring in use
  • Two-thirds of LPG sellers hold on to bulk importers to stay afloat in dollar crisis
    Two-thirds of LPG sellers hold on to bulk importers to stay afloat in dollar crisis
  • BNP declares fresh round of blockade on Tuesday-Wednesday
    BNP declares fresh round of blockade on Tuesday-Wednesday

Related News

  • India gives nod to Bharat Biotech for intranasal Covid booster doses
  • WHO issues emergency use listing for COVAXIN Covid-19 jab
  • India recommends homemade Covid-19 vaccine for kids aged 2 and above
  • India to miss end-July vaccination target as Bharat Biotech lags
  • India's Bharat Biotech says regulatory steps taken for Brazil vaccine contract

Features

Shashtho Chaka – Healthcare on Wheels has two buses, they plan to use one bus for the urban slums and another one for remote areas in villages.  Photos: Courtesy

Shashtho Chaka: Driving healthcare up to the doorstep of the poor

2h | Panorama
Russia has become increasingly critically dependent on Beijing. Even state-owned refiners in India are being pressured by Russian oil suppliers to pay in yuan.
Photo: Bloomberg

The yuan is finally showing some muscle in international trade

2h | Panorama
Khandaker Hasib Rafin’s Starlet Glanza V is one of the finest examples of the model to roam around Dhaka’s streets. Photo: Akif Hamid

1999 Starlet Glanza V: The uncrowned prince

19h | Wheels
Jamal Jamaloo: The song, dance and magic

Jamal Jamaloo: The song, dance and magic

21h | Features

More Videos from TBS

Wealth and income of ministers and state ministers increased

Wealth and income of ministers and state ministers increased

14h | TBS Stories
Fake toll plaza on Indian highway

Fake toll plaza on Indian highway

13h | TBS World
Farmers' investments fail to match returns: Study

Farmers' investments fail to match returns: Study

12h | TBS Economy
The US is sending another 14,000 shells to Israel

The US is sending another 14,000 shells to Israel

15h | TBS World
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]